| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
208,280,000 |
| Market
Cap: |
1.93(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.09 - $15.86 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, in vivo validation capabilities and a cross-functional team to discover medicines. Co.'s potential medicines include: REC-994 for the treatment of cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 for the treatment of familial adenomatous polyposis; REC-3599 for the treatment of GM2 gangliosidosis; REC-3964 for the treatment of C. difficile colitis; REC-64917 for neural or systemic inflammation; and multiple simultaneous programs in fibrosis developing with Bayer AG.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,693,990 |
| Total Buy Value |
$0 |
$0 |
$0 |
$12,897,789 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
27 |
| Total Shares Sold |
554,467 |
1,052,628 |
2,142,338 |
3,104,404 |
| Total Sell Value |
$4,901,427 |
$10,332,541 |
$21,057,672 |
$29,666,420 |
| Total People Sold |
4 |
6 |
8 |
8 |
| Total Sell Transactions |
22 |
44 |
94 |
152 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Doyle Ramona |
Chief Medical Officer |
• – – |
2022-02-04 |
4 |
D |
$11.40 |
$11,183 |
D/D |
(981) |
97,245 |
|
- |
|
| Doyle Ramona |
Chief Medical Officer |
• – – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
40,891 |
98,226 |
|
- |
|
| Larson Tina Marriott |
President and COO |
• – – |
2022-02-04 |
4 |
D |
$11.40 |
$9,439 |
D/D |
(828) |
129,518 |
|
- |
|
| Larson Tina Marriott |
President and COO |
• – – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
82,005 |
130,346 |
|
- |
|
| Secora Michael |
Chief Financial Officer |
• – – |
2022-02-04 |
4 |
D |
$11.40 |
$7,729 |
D/D |
(678) |
589,771 |
|
- |
|
| Secora Michael |
Chief Financial Officer |
• – – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
60,299 |
590,449 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-02-04 |
4 |
D |
$11.40 |
$3,910 |
D/D |
(343) |
234,020 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
210,893 |
234,363 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-01-31 |
4 |
S |
$11.73 |
$232,964 |
D/D |
(19,858) |
23,470 |
|
37% |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
19,858 |
43,328 |
|
- |
|
| Doyle Ramona |
Chief Medical Officer |
• – – |
2022-01-31 |
4 |
OE |
$2.48 |
$38,750 |
D/D |
15,625 |
57,335 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-01-14 |
4 |
S |
$13.57 |
$3,445,612 |
D/D |
(254,000) |
23,470 |
|
61% |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-01-14 |
4 |
A |
$0.00 |
$0 |
D/D |
254,000 |
277,470 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-01-13 |
4 |
S |
$14.26 |
$1,246,566 |
D/D |
(87,000) |
23,470 |
|
61% |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
87,000 |
110,470 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-01-05 |
4/A |
AS |
$7.39 |
$136,669 |
D/D |
(18,500) |
582,805 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-01-05 |
4/A |
A |
$0.00 |
$0 |
D/D |
18,500 |
601,305 |
|
- |
|
| Borgeson Blake |
Director |
– • – |
2022-01-04 |
4 |
AS |
$18.03 |
$173,528 |
D/D |
(9,625) |
7,651,146 |
|
-69% |
|
| Doyle Ramona |
Chief Medical Officer |
• – – |
2022-01-03 |
4 |
OE |
$2.47 |
$99,595 |
D/D |
40,322 |
40,322 |
|
- |
|
| Burrell Terry-Ann |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
763 |
134,585 |
|
- |
|
| Bogue Zachary |
Director |
– • • |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
589 |
1,370 |
|
- |
|
| Hershberg Robert |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
693 |
7,862 |
|
- |
|
| Chavez R Martin Phd |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,040 |
8,669 |
|
- |
|
| Borgeson Blake |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
555 |
7,660,771 |
|
- |
|
| Li Dean Y |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
659 |
597,922 |
|
- |
|
641 Records found
|
|
Page 22 of 26 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.18 (1.91%) 
